Goodwin Procter and Wilson Sonsini Goodrich & Rosati represented MBX Biosciences, Inc. in the offering, and Davis Polk & Wardwell represented the underwriters. MBX Biosciences, Inc....
MBX Biosciences’ $187.7 Million IPO
Relay Therapeutics’ $200 Million Follow-on Offering
Goodwin Procter and Dechert advised Relay Therapeutics, Inc. in the offering, and Ropes & Gray advised the underwriters. Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision...
AVROBIO’s Merger with Tectonic Therapeutic
Leerink Partners is serving as exclusive financial advisor to Tectonic and Cooley LLP is serving as legal counsel to Tectonic. Leerink Partners and TD Cowen are...
Metagenomi’s $94 Million Initial Public Offering
Goodwin assisted Metagenomi on the matter. Preclinical biotech Metagenomi went public on the Nasdaq under the ticker “MGX”, raising $94 million by offering 6.25 million shares...
Pathos AI’s Acquisition of Rain Oncology
Leerink Partners is acting as exclusive financial advisor and Gibson, Dunn & Crutcher LLP is acting as legal counsel to Rain. Goodwin Procter LLP is acting...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Eli Lilly’s $1.925 Billion Acquisition of Versanis Bio
Kirkland & Ellis acted as legal counsel to Eli Lilly, while for Versanis, Goodwin Procter acted as legal counsel and Cooley advised as to patent matters....
TCR² Therapeutics’ Agreement with Adaptimmune Therapeutics
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
Fulcrum Therapeutics’ $125 Million Public Offering of Common Stock
Goodwin Procter advised Fulcrum Therapeutics on the deal. Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced its underwritten public offering of 9,615,384 shares of its common stock at...
Regeneron Pharmaceuticals’ Acquisition of Checkmate Pharmaceuticals
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
Global Blood Therapeutics’ $345 Million Notes Offering
Goodwin Procter advised Global Blood Therapeutics on the deal. Global Blood Therapeutics, Inc. (Nasdaq: GBT) announced its offering of 1.875% Convertible Senior Notes due 2028. The...